The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion Webcast (2024)

This comprehensive, interactive course equips urologic professionals with the knowledge and skills needed to effectively manage patients with advanced prostate cancer. Through an in-depth exploration of guidelines, treatment modalities, and emerging therapies, participants will gain a thorough understanding of this complex disease and its evolving landscape.

As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the most updated Advanced Prostate Cancer: AUA/SUO Guideline. Topics will include the latest on Multidisciplinary Care Models, Genetic Testing, Next Generation Imaging (PSMA) and Introduction to Theranostics, M1 CRPC First and Second Line Treatment Options, PARP Inhibitors, Microsatellite Instability, and Precision Medicine, and Treatment Sequencing and Future Directions.



This educational activity is supported by independent educational grants from:

  • Astellas
  • AstraZeneca
  • Bayer HealthCare Pharmaceuticals Inc.
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Merck & Co., Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.

Target Audience

  • Urologists
  • Fellows
  • Residents
  • Advanced Practice Providers (Nurse Practitioners & Physician Assistants)
  • Non-Urologists (MD or DO)

Learning Objectives

At the conclusion of this activity, participants will be able to:  


  1. Describe the natural course of advanced prostate cancer from biochemical recurrence to metastatic hormone-sensitive disease (mHSPC), with progression to the development of non-metastatic (M0CRPC) and metastatic castration-resistant disease (mCRPC).
  2. Describe the risk stratification, treatment options, goals of therapy and outcomes for patients with biochemical recurrence after failed local therapy.
  3. Identify available imaging and indications for use of advanced imaging including PSMA PET imaging including for staging to determine metastatic disease in unfavorable intermediate and high-risk patients and for detecting and localizing lesions at biochemical recurrence after failed local therapy.
  4. Describe the risk and volume stratification, treatment options, goals of therapy and outcomes for newly diagnosed mHSPC including treatment intensification and novel hormonal therapy agents.
  5. Explain the implications of CRPC on the management of both M0 and M1, including sequencing of agents and combination therapy.
  6. Discuss the molecular mechanisms and characterization of CRPC.
  7. Discuss the incorporation of genetic testing (both germline and somatic testing) into the management of men with high risk, metastatic prostate cancer and CRPC and implications for treatment.
  8. Explain the role of precision-based medicine the treatment of men with advanced prostate cancer (APC).


  1. Discuss recommendations within the 2023 Updated AUA Advanced Prostate Cancer Guidelines.
  2. Discuss the impact of new FDA-approved agents on the management of men with APC.
  3. Define M0 CRPD, the treatment options and goals of therapy.
  4. Discuss clinically meaningful endpoints in clinical trials of patients with M0 CRPC.
  5. Describe gaps in the knowledge for treatment and sequencing of agents in the management of CRPC.
  6. Discuss challenges in incorporating AUA APC Guidelines and management of advanced mHSPC and CRPC into community practice.


  1. Identify approved androgen biosynthesis and receptor blockers for treatment of CRPC.
  2. Appraise the clinical use and efficacy of approved androgen-axis therapeutics for CRPC.
  3. Anticipate, manage and treat adverse events from therapeutic interventions directed at the androgen-axis used in the treatment of CRPC.
  4. Discuss new uses for androgen axis agents in M0 CRPC.


  1. Identify approved chemotherapeutics, immunotherapy, PARP Inhibitors and theranostics for mCRPC.
  2. Describe indications and contraindications for chemotherapy, immunotherapy, PARP Inhibitors and theranostics in patients with mCRPC.
  3. Identify co-morbid states and recognize their impact on treatment options for mCRPC.
  4. Identify germline and somatic mutations and implications for treatment in mCRPC including indications for PARP Inhibitors.
  5. Identify candidates for theranostic therapy using novel PSMA PET imaging.
  6. Discuss treatment sequencing in the advanced, metastatic and CRPC disease state.


  1. Integrate advances in bone health management into patient-specific care plans.
  2. Identify and prescribe radionuclide therapy in appropriate patients with symptomatic mCRPC.
  3. Discuss known adverse events associated with androgen biosynthesis inhibitors and radionuclide therapy.


  1. Assess and manage pain in patients with symptomatic mHSPC and mCRPC.
  2. Discuss the role of chemotherapy, performance status and pain management in mCRPC.
  3. Review the role of palliative care and supportive services in the management of late stage CRPC.
Course summary
Available credit: 
  • 4.75 AMA PRA Category 1 Credit™
  • 4.75 Non-Physician Participation
Course opens: 
Course expires: 

Faculty Disclosures

PDF iconFaculty Disclosures

Education Council Disclosures

PDF iconEducation Council Disclosures

COI Review Work Group Disclosures

PDF iconCOI Review Work Group Disclosures


AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2024
Expiration Date: May, 2025

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 4.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 4.75 AMA PRA Category 1 Credit™
  • 4.75 Non-Physician Participation
Please login or register to take this course.